Search

Your search keyword '"Robinson, Simon"' showing total 9,209 results

Search Constraints

Start Over You searched for: Author "Robinson, Simon" Remove constraint Author: "Robinson, Simon"
9,209 results on '"Robinson, Simon"'

Search Results

154. Data from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition

155. Supplementary Data from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition

156. Data from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes

157. Data from The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN-Amplified Neuroblastoma In Vivo

158. Supplementary Data from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes

159. Supplementary Figure Legends 1-5 from The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN-Amplified Neuroblastoma In Vivo

160. Supplementary Table S3 from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes

161. Supplementary Figures 1-5 from The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN-Amplified Neuroblastoma In Vivo

162. Regulation of immune responses in primary biliary cholangitis: a transcriptomic analysis of peripheral immune cells

163. Analytic result variation for high-sensitivity cardiac troponin: Interpretation and consequences

164. Supplementary Figure Captions from Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI

165. Supplemental Movie 2: Interstitial convection, vascular perfusion and the location of blood vessels in an LS174T tumor from Investigating Low-Velocity Fluid Flow in Tumors with Convection-MRI

166. Supplemental Movie 3: Interstitial convection and vascular perfusion in an LS174T tumor from Investigating Low-Velocity Fluid Flow in Tumors with Convection-MRI

167. Supplemental Movie 1: Convection-MRI sequence from Investigating Low-Velocity Fluid Flow in Tumors with Convection-MRI

168. Data from MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Antiangiogenic Treatment

169. Supplementary Tables from In Vivo Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis

170. Supplemental Movie 5: Interstitial convection and Gd-DTPA enhancement with time in an LS174T tumor from Investigating Low-Velocity Fluid Flow in Tumors with Convection-MRI

171. Supplementary Materials and Methods from Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma

172. Supplementary Figure Legends from Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma

173. Data from Investigating Low-Velocity Fluid Flow in Tumors with Convection-MRI

174. Data from Noninvasive MRI Native T1 Mapping Detects Response to MYCN-targeted Therapies in the Th-MYCN Model of Neuroblastoma

176. Supplementary Figure 1 from Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI

177. Supplementary Fig. 3 from In Vivo Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis

178. Supplementary Figure 2 from Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI

179. Supplementary Figure 5 from CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

180. Supplementary Data from Investigating the Contribution of Collagen to the Tumor Biomechanical Phenotype with Noninvasive Magnetic Resonance Elastography

181. Supplementary Fig. 1 from In Vivo Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis

183. Supplementary figures S1-8 from Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma

184. Supplementary Figure 3 from CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

185. Supplemental Movie 4: Interstitial convection and vascular perfusion in an SW1222 tumor from Investigating Low-Velocity Fluid Flow in Tumors with Convection-MRI

186. Data from Investigating the Contribution of Collagen to the Tumor Biomechanical Phenotype with Noninvasive Magnetic Resonance Elastography

187. Supplementary Figure 6 from Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI

188. Data from In Vivo Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis

189. Supplementary Figure 5 from Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI

191. Supplementary Figure 4 from CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

192. Supplementary Figure Legend from CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

194. Supplementary Data from Noninvasive MRI Native T1 Mapping Detects Response to MYCN-targeted Therapies in the Th-MYCN Model of Neuroblastoma

195. Supplementary Data from MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Antiangiogenic Treatment

196. Supplementary Fig. 6 from In Vivo Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis

197. Supplementary Table 1 from CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

198. Supplementary Table 2 from CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

199. Supplementary Fig. 2 from In Vivo Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis

200. Supplementary Fig. 5 from In Vivo Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis

Catalog

Books, media, physical & digital resources